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Abstract. Factor analysis (FA) has become part and parcel in metabolic
syndrome (MBS) research. Both exploration- and confirmation-driven factor
analyzes are rampant. However, factor analytic results on MBS differ widely.
A situation that is at least in part attributable to misapplication of FA. Here,
our purpose is (i) to review factor analytic efforts in the study of MBS with
emphasis on misusage of the FA model and (ii) to propose an alternative factor
analytic strategy.
Methods: The proposed factor analytic strategy consists of four steps and con-
fronts weaknesses in application of the FA model. At its heart lies the explicit
separation of dimensionality and pattern selection as well as the direct eval-
uation of competing inequality-constrained loading patterns. A high-profile
MBS data set with anthropometric measurements on overweight children and
adolescents is reanalyzed using this strategy.
Results: The reanalysis implied a more parsimonious constellation of patho-
physiological domains underlying phenotypic expressions of MBS than the
original analysis (and many other analyzes). The results emphasize correlated
factors of impaired glucose metabolism and impaired lipid metabolism.
Conclusions: Pathophysiological domains underlying phenotypic expressions
of MBS included in the analysis are driven by multiple interrelated metabolic
impairments. These findings indirectly point to the possible existence of a
multifactorial aetiology.
Key words: Factor analysis; Metabolic syndrome
Abbreviations: AACE = American Academy of Clinical Endocrinologists; BMI
= body mass index; CFA = confirmatory factor analysis; CVD = cardiovascu-
lar disease; DBP = diastolic blood pressure; DM = diabetes mellitus; EFA =
exploratory factor analysis; EGIR = European Group for study of Insulin Re-
sistance; FA = factor analysis; G2 blood glucose level two hours after oral glu-
cose intake; GB = blood glucose level at (fasting) baseline; HDL chol. = high
density lipoprotein cholesterol; HOMA = homeostatic model assessment; IR
= insulin resistance; MBS = metabolic syndrome; NCEP ATPIII = National
Cholesterol Education Program - Adult Treatment Panel III; PCA = princi-
pal components analysis; SBP = systolic blood pressure; trig. = triglycerides;
UCFM = unrestricted confirmatory factor model; WHO = World Health Or-
ganization
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1. Introduction
Certain risk factors for type 2 diabetes mellitus (DM) and atherosclerotic car-
diovascular disease (CVD) have long been observed to cluster together in the in-
dividual [1, 2]. This clustering has rendered renewed interest with Reaven’s con-
tention [3, 4] that insulin resistance forms its basis. Today, the complex of in-
terrelated risk factors of metabolic origin is known as the ‘metabolic syndrome’
(MBS) [5, 6]. It is considered to be a major threat to current and future public
health, especially as MBS might result from maladaptive human metabolism in the
face of food energy abundance in combination with a sedentary lifestyle [7, 8].
Recently, the MBS concept has been hotly debated [9–18]. A number of inter-
related reasons are at the heart of the debate. The aetiology of the syndrome is
largely unknown as to date it is unclear if a single pathogenetic process promotes
the syndrome, or if multiple different pathogenetic processes need to concur in order
for the syndrome to express itself. Notwithstanding the unknown aetiology, a num-
ber of expert groups, among which the World Health Organization (WHO) [19] and
the National Cholesterol Education Program - Adult Treatment Panel III (NCEP
ATPIII) [20], have published (slightly) different definitions of MBS intended for
clinical diagnosis. However, clinical evidence on whether MBS is a better predictor
of CVD and DM risk than its individual components, is equivocal [10,21].
The stance on the MBS concept taken here is the following. The aetiology does
not have to be known for the existence of a condition to be accepted [17], as is
the case with, for example, type 2 DM. Current knowledge is however limited,
such that MBS is not considered a clinical entity, but rather as defining a state of
heightened risk for DM and CVD. The syndromic approach taken is epidemiologi-
cal rather than clinical. In the sense that MBS is deemed to provide a conceptual
framework for the clustering of metabolic risk factors. An important step in fur-
thering epidemiologic understanding of the syndrome is then an assessment of the
pathophysiological constellation of what are deemed to be phenotypic expressions
of MBS. A constellation we believe to be driven, not by insulin resistance [3,4], but
by multiple interrelated metabolic impairments [22].
Factor analysis (FA) has become an oft-used tool for evaluations of phenotypic
domains underlying MBS [23]. FA is a multivariate technique that may reveal a pat-
tern of reduced dimensionality among a larger set of intercorrelated variables [24].
FA, however, is often poorly understood while being routinely executed [25], lead-
ing to diffuse findings and possibly confusing efforts in understanding MBS. This
paper aims to review factor analytic efforts in the study of MBS, with emphasis on
misusage of FA. An alternative factor analytic strategy is proposed that confronts
weaknesses in the application of FA. A high-profile MBS data set with anthropomet-
ric measurements on overweight and obese children and adolescents is reanalyzed
using the alternative strategy. The findings may give renewed cachet to both FA
and its connection to MBS research.
2. Assessing Factor Analytic Efforts in MBS Research
2.1. The Factor Analytic Model. FA has come to be heavily utilized in the
MBS research community since its seminal usage by Edwards, et al. [26]. An im-
portant question thrusting the FA efforts in MBS research is if a unifying physiology
dominated by insulin resistance underlies the clustering of metabolic risk variables,
or if there are multiple underlying physiologic phenotypes.
PATHOPHYSIOLOGICAL DOMAINS UNDERLYING THE METABOLIC SYNDROME 3
The common factor analytic model assumes that a random p-dimensional vector
of observed variables can be grouped by their covariances or correlations into a
lower-dimensional linear combination of latent variables:
(1)
zi = µ + Λ · ξi + i
(p× 1) (p× 1) (p×m) (m× 1) (p× 1) .
In (1) zi denotes the (possibly standardized) observed variable of dimension p for
person i, µ denotes the intercept, i denotes the error measurements for person i,
and Λ is a (p × m)-dimensional matrix of factor loadings in which each element
λjk is the loading of the jth variable on the kth factor, j = 1, . . . , p, k = 1, . . . ,m.
Then ξi represents a latent variable of dimension m, with m < p, whose elements
are referred to as common factors. In effect, FA represents a method of identify-
ing or specifying latent factors that account for the (co)variances among observed
variables by partitioning observed variance into common variance (attributable to
the underlying latent common factors) and unique variance (among which are er-
ror components) [24]. In the standard model the random variables zi, ξi, and i
are assumed to have Gaussian distributions, although the development of robust
estimation procedures (e.g., [27, 28]) have somewhat softened the necessity of this
assumption. (See Appendix ‘Basics of Factor Analysis’ for a more detailed overview
of the FA model). The model can have both explorative and confirmative thrusts.
Before assessing these thrusts some general remarks on FA are made.
A first general comment on the utilization of FA by the MBS research commu-
nity is that basic model assumptions are seldom assessed. The model boasts several
implicit assumptions such as a nonsingular sample covariance matrix and a reason-
able proportion of variance among the observed variables being common variance.
The appropriateness of these assumptions is easily [29] but rarely assessed. More-
over, the explicit distributional assumptions imply usage of observed variables of
continuous metric and disqualifies the common FA model for binary and categorical
observed data. Many MBS studies, however, employ standard FA on variables of
non-continuous metric. In such situations extensions of the standard FA model are
needed [30,31].
A second general comment concerns interpretational overextension. The FA
model cannot determine existence of MBS nor assess clinical importance of MBS as
a concept [25]. What FA can do is, through the latent factors (when adhering to a
realist ontology [32]), give indications of pathophysiological domains that underlie
phenotypic expressions of MBS.
2.2. Comments on Exploratory Efforts. In exploratory FA (EFA) both m and
the meaning of latent factors are unknown. In the exploratory sense, FA is a theory-
generating technique used for the identification of meaningful latent factors. Most
MBS studies utilize FA in the exploratory sense [33–43]. Many deployments of EFA
are however suboptimal.
EFA is often confused with principal components analysis (PCA). PCA is a
data-reductional technique, seeking to identify components. It resembles the model
in (1) without inclusion of error measurements, leading the components to differ
conceptually and mathematically from latent factors in EFA [44]. Components are
weighted linear combinations of observed variables seeking to efficiently explain
observed variance in the data [45], leaving the explanation of observed covariance
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secondary [44]. Many MBS studies employing FA, however, seek to obtain an ex-
planation of the observables’ covariation through a small number of explanatory
factors. Also, a phenotype is just an expression of genotype or pathophysiology, in-
dicating the necessity of including measurement error. As such, employing common
EFA would be more appropriate.
An important decision in EFA is determining the number of factors to retain.
Many methods are heuristical, relying on subjective judgments or arbitrary cut-
off values. The Guttman-Kaiser rule [46, 47] is the most popular rule of thumb. It
states that one should retain at most those factors associated with eigenvalues whose
magnitude exceeds the average eigenvalue (the average eigenvalue being 1 when
using standardized data). This criterion, as well as many other heuristical factor
retention criteria, are prone to under- (retaining too few factors) and overfactoring
(retaining too many factors) [48,49].
Given the above it is disconcerting that factor analytic efforts in MBS research
are usually based on what has been termed ‘Little jiffy’ [29]: Employment of PCA,
retainment of components based on the Guttmann-Kaiser rule followed by a Vari-
max rotation [50], and the subsequent interpretation of rotated components as if
they were common factors. Such mechanical use of EFA stunts learning and inter-
pretation [51], and is (in part) responsible for the widely differing results obtained
with EFA in MBS research. See the online supplement to this paper for an overview
of the disparate results obtained with EFA as well as confirmatory FA (next sub-
section).
2.3. Comments on Confirmatory Efforts. Confirmatory FA (CFA) is a theory-
testing technique. An a priori factor structure is assumed, with given m, with a
pre-specified loadings matrix in which exclusion constraints indicate which variables
are indicators of which latent factor(s), and with possibly correlated factors and
error variances. The model or models stated then remain to be tested. CFA studies
are gaining interest in MBS research [52–58]. Standard CFA however, can also be
misapplied.
The evaluation of model fit in CFA is essentially the evaluation of a diffuse
hypothesis as it is unclear in case of misspecification if the pattern of loadings or
the factor dimensionality is to blame [59]. Moreover, specifying a pattern of factor
loadings through exclusion restrictions implies a loss of information in the sense that
more exclusion restrictions are applied than is usually necessary for identification
of the FA model. Additionally, exclusion restrictions may amount to errors of
omission, may make the unrealistic assumption that items are factorially pure (in
the population), and may induce bias in estimates of the free parameters [60, 61].
These issues are intricately connected to the well-known and widespread situation
of exploratively obtained factor structures not being confirmed by CFA [60].
Some recent CFA studies in MBS research claim to provide evidence that a sin-
gle latent factor underlies MBS [53, 55, 58]. These studies include four observed
variables, some of which are functions of several variables usually employed as sep-
arate phenotypic items. This practice (called parceling) is justified by the claim
that utilization of multiple measures for what is believed to be a trait will lead
to a model with multiple factors, thus clouding efforts to establish a single la-
tent factor underlying MBS. However, the inclusion of multiple sets of correlated
measures does not irrevocably lead to a model with more than one latent factor,
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unless some measures would identify a doublet factor (see Section ‘Step 1: Dimen-
sionality Selection’ below). Also, the mentioned CFA efforts may actually provide
evidence for a hierarchical latent factor [52] rather than a single pathophysiological
domain underlying MBS, as the usage of functions of variables implies a (partial)
pre-compression of the data. Parceling changes the nature of the data, may mask
model misspecification and thus may inflate goodness-of-fit (indices) [62] (cf. [63]).
Indeed, “it is possible to argue (inappropriately) that a single factor solution pro-
vides a good fit to the data under apparently benign parceling strategies” [62].
Moreover, while a two-factor model can be modeled on four variables, such a model
would not be meaningful given that the observables were constructed to represent
a single factor; implying that the one-factor model is the only model to be mean-
ingfully fitted on the four observed variables. The possibility to assess if there are
multiple (related) pathophysiological domains underlying phenotypic expressions of
MBS is then denied. A meaningful scientific method, however, allows for multiple
competing theories to be tested [64], as single hypotheses suffer from confirmation
bias.
3. An Alternative Factor Analytic Strategy
An alternative confirmatory factor analytic strategy is proposed that aims to
confront the weaknesses in the application of FA. In a sense the strategy seeks to
bridge the EFA – CFA divide so as to increase the inferential power of a factor
analysis. This strategy is embedded within the Bayesian model selection approach,
whose analytical advantages have been well documented [65]. The main Bayesian
model selection criterion is the Bayes factor. This quantity incorporates model
fit as well as model complexity and expresses “the evidence provided by the data
in favor of one scientific theory, represented by a statistical model, as opposed to
another” [66]. It can be used to compare any two models. Using Bayes factors,
one can compute posterior model probabilities, which, assuming a uniform prior
on the model space, are normalized Bayes factors. These quantities express model
(un)certainty, in the sense that posterior model probabilities can be interpreted as
the relative amounts of support in the data for the models under consideration.
See Appendix ‘A Primer on Bayesian Statistics’ for more information on the Bayes
factor and posterior model probabilities.
The strategy proposed consists of the following steps:
Step 1: Determine formally the (intrinsic) number of common factors based
on a weighing of model fit and model complexity. For example along the
lines specified in Peeters [67], who uses a Bayesian EFA model for selecting
the optimal dimension m;
Step 2: Whence settled on latent factor dimensionality m, specify an un-
restricted confirmatory factor model (UCFM). An UCFM is a FA model
that corresponds to EFA in the sense that only minimal restrictions are
placed on the factor loadings matrix and the factor covariance matrix for
achieving global rotational uniqueness of the factor solution. However, the
restrictions are to be chosen such that they convey preconceived theoretical
meaning and thus render unnecessary post-hoc rotation of the solution for
interpretation purposes. Peeters [68] gives minimal conditions for specifying
a UCFM;
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Step 3: Formulate, using the UCFM obtained in Step 2 as a base model,
competing inequality constrained factor structures making use of inequal-
ity constraints on and between the free parameters in the loadings ma-
trix. Substantive theory is then not represented by exclusion restrictions
to express a pre-specified factor loading pattern, but by the imposition of
inequality constraints;
Step 4: Compute the posterior model probability for each constrained model
under consideration and determine the constrained model most supported
by the data.
The strategy explicitly encourages the formulation of competing inequality con-
strained theories for (statistical) scrutiny. When used in full, the thrust of the
sequence is confirmatory, with the explicit separation of dimensionality and pat-
tern selection in order to avoid embarking on diffuse hypotheses.
4. Reanalysis of Data by Weiss et al. [69]
4.1. Data. The data have been described elsewhere [69]. It considers a multiethnic,
multiracial cohort of 464 nondiabetic obese and overweight children and adolescents.
The data contain measurements on the body mass index (BMI), blood glucose level
at (fasting) baseline (GB) and two hours after (G2) oral glucose intake (both in
mg/dl), fasting levels of triglycerides (trig.; mg/dl) and high-density lipoprotein
(HDL) cholesterol (mg/dl), systolic and diastolic blood pressure (SBP, DBP; both
in mm Hg), and insulin resistance (IR). IR was measured through homeostatic
model assessment (HOMA). For more information on the data, see Weiss et al. [69].
Consideration of pediatric samples is important as current prevalence of MBS
among youngsters may give indications of the future burden of DM and CVD. The
measurements are in line with the American Academy of Clinical Endocrinologists
(AACE) position on MBS [70], which emphasizes the epidemiologic pathophysio-
logical perspective. The inclusion of IR makes it possible to test theories regarding
the importance of IR in the MBS construct.
The little jiffy approach was the original factor analytic strategy for analyzing
the data [69]. Here, the alternative strategy will be utilized for reanalysis. As in
Weiss et al. [69], the natural logarithm was taken of the glucose, insulin resistance
and triglycerides measurements to abide the normality assumption. The data were
standardized such that a case of modeling the correlation matrix is considered.
The sample correlation matrix is nonsingular and the Kaiser-Meyer-Olkin test [29]
indicates that a reasonable proportion of variance among the variables might be
common variance.
4.2. Step 1: Dimensionality Selection. Posterior model probabilities are com-
puted for each model allowed by the condition (p−m)2−p−m > 0. This inequality
simply states that the number of nonredundant elements in the sample covariance
matrix must be greater than or equal to the number of freely estimable parameters
in the model, which places an upper bound on m. The data have eight measured
variables (p = 8), giving that the maximum number of factors that can be extracted
equals m = 4. The computation strategy couples the candidate estimator method
for computing Bayes factors [71] with the use of training samples [72]. This prac-
tice allows one to obtain determinate Bayes factors and subsequent posterior model
probabilities using standard diffuse conjugate or noninformative priors [73]. The
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computation strategy is embedded within a search strategy too weed out models
suffering from rank deficiency in Λ as this is a direct indicator for overfactoring
(see (6) in Appendix ‘Basics of Factor Analysis’). This search excludes the m = 4
model. The following posterior model probabilities are obtained when assuming
that each model is equally likely a priori : P (m = 1|Z) = 0; P (m = 2|Z) = 1; and
P (m = 3|Z) = 0. The data thus support the two-factor model.
These results differ from Weiss et al. [69] and several other factor analytic ef-
forts in which a three-factor (or higher) solution was found. A first reason for the
retention of more latent factors in these studies is the tendency of heuristic factor-
selection rules to overfactor [48,49]. More formal selection procedures, such as the
likelihood ratio test in maximum likelihood EFA and the assessment of information
criteria, do not escape this tendency [74,75].
Another reason for the higher factor solution in other studies might be the ex-
istence of doublet factors. Doublet factors are factors that arise as the result of
common variance due to correlation between just two variables [24]. Doublet fac-
tors are considered to be conceptually weak factors and the assignment of an in-
dependent latent construct to a doublet factor is contentious. SBP and DBP are
variables that, within the battery of measurements on phenotypic expressions of
MBS, usually correlate only with each other resulting in a doublet factor to be
extracted (usually termed ‘hypertension’). The strategy employed here sees past
the doublet factor and indicates the more parsimonious model with two factors as
optimal.
4.3. Step 2: Base Model Formulation. A UCFM for m = 2 will be formulated
for confirmatory efforts. Abiding conditions given by Peeters [68], the following
minimal restrictions on Λ are chosen for global rotational uniqueness:
Λ0 =

λ11 λ12
λ21 λ22
λ31 = 0 λ32 > 0
λ41 λ42
λ51 > 0 λ52 = 0
λ61 λ62
λ71 λ72
λ81 λ82

BMI
loge{trig.}
HDL chol.
loge{IR}
loge{GB}
loge{G2}
SBP
DBP
.
The exclusion restrictions {λ31, λ52} = 0 identify the model up to polarity rever-
sals in the columns. The polarity truncations {λ32, λ51} > 0 then ensure global
rotational uniqueness of the model. These constraints are chosen for the following
reasons. First, from prior knowledge and previous analyzes a two-factor solution
is deemed to consist of a glucose and a lipid factor. HDL chol. is then believed
to have a large loading on a lipid (second) factor while having a small loading
on the first factor, and loge{GB} is believed to have a large loading on a glucose
(first) factor while having a small loading on the second factor. These variables
then serve as an indicator of the respective factors. It is thus reasonable to specify
{λ31, λ52} = 0 and {λ32, λ51} > 0. Second, the chosen minimal restrictions comply
with all competing inequality constrained formulations of factor structure to be
assessed.
4.4. Step 3: Formulating Competing Constrained Factor Structures. Fac-
tor structure for confirmatory efforts is not represented using exclusion restrictions
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but by imposing inequality constraints on and between the parameters left free in
the UCFM. The following inequality constrained competing factor structures are
formulated:
Λ1 =

λ11 > |λ12|
|λ21| < −λ22
λ31 = 0 λ32 > 0
λ41 > |λ42|
λ51 > 0 λ52 = 0
λ61 > |λ62|
λ71 > |λ72|
|λ81| < −λ82

BMI
loge{trig.}
HDL chol.
loge{IR}
loge{GB}
loge{G2}
SBP
DBP
,
Λ2 =

|λ11| < −λ12
|λ21| < −λ22
λ31 = 0 λ32 > 0
λ41 > .4 λ42 < −.4
λ51 > 0 λ52 = 0
λ61 > |λ62|
λ71 < −λ72
λ81 < −λ82

BMI
loge{trig.}
HDL chol.
loge{IR}
loge{GB}
loge{G2}
SBP
DBP
,
Λ3 =

λ11 > |λ12|
|λ21| < −λ22
λ31 = 0 λ32 > 0
λ41 > |λ42|
λ51 > 0 λ52 = 0
λ61 > |λ62|
|λ71| < .3 |λ72| < .3
|λ81| < .3 |λ82| < .3

BMI
loge{trig.}
HDL chol.
loge{IR}
loge{GB}
loge{G2}
SBP
DBP
.
A formulation like λ71 < −λ72 states that the negative of λ72 is believed to be
larger than λ71. Note that this is a much more informative formulation than the
more usual strategy of setting λ71 = 0 and letting λ72 be free to be estimated in
order to express the belief that SBP is an indicator for the second latent factor
rather than the first one. In the same respect, a formulation like
λ61 > |λ62| ⇒
{
λ61 − λ62 > 0
λ61 + λ62 > 0
,
indicates the belief that λ61 is larger than λ62, irrespective of the latter’s sign. A
statement like
|λ82| < .3⇒ −.3 < λ82 < .3,
indicates the belief that λ82 takes a value in the interval [−.3, .3].
In all models insulin resistance, blood glucose level at baseline and two hours
after glucose intake are mainly related to the glucose factor, while fasting levels
of triglycerides and HDL cholesterol form the base of the lipid factor. Note that
for the lipid factor polarity fixation is brought about by demanding λ32 > 0. HDL
cholesterol is generally regarded as ‘good’ cholesterol, meaning that the choice λ32 >
0 amounts to modeling a factor denoting unimpaired lipid metabolism. Hence
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formulations like |λ21| < −λ22, as under given polarity truncation the triglycerides
item is believed to be strongly negatively related to a lipid factor.
Model 1 adds detail to the base model and the basic factors by stating that
BMI and systolic blood pressure are linked to the glucose factor (λ11 > |λ12|,
λ71 > |λ72|), while diastolic blood pressure is believed to be linked to the lipid
factor (|λ81| < −λ82). Model 2 states the hypothesis that BMI is an indicator
for the lipid rather than the glucose factor (|λ11| < −λ12). Also, in this model
both systolic and diastolic blood pressure are related to the lipid rather than the
glucose factor, with the additional belief that both blood pressure measures will
load positively on the latter (λ71 < −λ72, λ81 < −λ82). Moreover, the second
model states that insulin resistance may be the measure tying MBS together. In a
multifactor model this would imply that the insulin resistance measure achieves a
large or dominant loading on both the glucose and lipid factor (λ41 > .4, λ42 < −.4).
Model 3 resembles the first model, but states that the association of systolic and
diastolic blood pressure with the factors is rather loose.
4.5. Step 4: Constrained-Model Selection and Interpretation. Bayes fac-
tors for models under inequality constraints are easily computed [76]. Again, stan-
dard (diffuse) conjugate and noninformative priors are utilized. Assuming a uniform
prior on the model space the following posterior model probabilities are obtained
for the constrained two-factor models under consideration: P (M1|Z) = .0004;
P (M2|Z) = 0; and P (M3|Z) = .9996. Conditioned on the data, the third model
receives almost all support.
The third constrained model connects trig. and HDL chol. to a lipid metabolism
factor and IR, GB, and G2 to a glucose metabolism factor. Moreover, the model
states that BMI is related to the glucose metabolism factor rather than the lipid
metabolism factor. The finding that blood pressure is not an independent patho-
physiological factor is consistent with epidemiologic evidence that insulin resistance
and lipid metabolism play a role in the pathogenesis of hypertension rather than
hypertension being a physiologic phenotype [22].
Table 1. Posterior Means and 95% Credible Intervals for Λ0
Factor 1 Factor 2
Parameter Mean 95% CI Parameter Mean 95% CI Item
λ11 .324 [ .207, .440] λ12 -.068 [-.191, .055] BMI
λ21 -.006 [-.303, .215] λ22 -.653 [-.956,-.379] loge{trig.}
λ31 - - λ32 .706 [ .442, .940] HDL chol.
λ41 .767 [ .613, .921] λ42 -.179 [-.343,-.022] loge{IR}
λ51 .470 [ .360, .585] λ52 - - loge{GB}
λ61 .355 [ .205, .492] λ62 -.124 [-.289, .036] loge{G2}
λ71 .274 [ .136, .416] λ72 .029 [-.118, .171] SBP
λ81 .202 [ .069, .347] λ82 .139 [-.017, .292] DBP
The estimates of the UCFM given in Table 1 also lend support to model 3.
(Confer Appendix ‘Results Factor Analytic Approach Weiss et al. [69]’ to see, in
contrast, the parameter estimates obtained with the little jiffy approach of the
original study [69]). The table contains posterior means and credible intervals. A
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credible interval is a posterior probability interval. For example, the posterior prob-
ability that λ11 lies in the interval [.207, .440] is .95. (See Appendix ‘Reproduced
Correlation Structure’ for an indication of the success of the two-factor UCFM in
retrieving the sample correlation matrix).
The estimates indicate that the hypertension variables seem to be relatively weak
in their association with the respective factors. The credibility intervals indicate
that these variables are mostly related to the glucose metabolism factor, which
would be in line with the hypothesis that hypertension is related to insulin resistance
and impaired glucose metabolism [3, 4]. Regarding the contention that insulin
resistance is the basis for MBS: IR is related to both the glucose and lipid factors.
However, the posterior mean of the loading tying IR to the lipid metabolism factor
is relatively small and the upper bound of its credibility interval approaches zero.
The second inequality constrained model is thus rightly not supported by the data.
The two latent factors are appreciably correlated with a posterior mean of −.277
and a 95% credible interval of [−.417,−.137]. Note that, as stated in Section ‘Step
3: Formulating Competing Constrained Factor Structures’, the second factor mod-
els unimpaired lipid metabolism. Thus, the selected model indicates that, given the
data and measurements, impaired glucose metabolism and impaired lipid metabo-
lism are positively related pathophysiological domains. Moreover, the two factors
connect to two main hypotheses regarding syndrome aetiology, stating that the
risk-factor associations are due to abnormality of the insulin/glucose metabolism
and/or abnormality of the lipid metabolism [22].
5. Discussion
Applications of FA in MBS research were evaluated. Lacunae in both EFA and
CFA were discussed. It is argued that the mechanical use of EFA and misunder-
standings of CFA are, at least in part, responsible for the widely differing results
obtained with FA on data with phenotypic expressions of MBS.
An alternative factor analytic strategy is proposed. The strategy consists of
four steps and aims to confront the weaknesses in application of the FA model, by:
(i) Formally assessing optimal choice of factor dimensionality; (ii) Canceling the
need for post-hoc rotation of the factor solution; (iii) Allowing to express a con-
firmatory factor structure through informative inequality constraints rather than
through rigid exclusion restrictions; (iv) Encouraging the formulation of compet-
ing inequality constrained theory-based expressions of factor structure, in order to
avoid confirmation bias.
The alternative strategy was utilized in reanalyzing a high-profile data set on
which factor analyzes were previously employed. The data consider eight variables
as phenotypic expressions of MBS in a cohort of nondiabetic overweight and obese
children and adolescents [69]. The reanalysis based on the alternative strategy
implied a more parsimonious constellation of pathophysiological domains under-
lying phenotypic expressions of MBS than the original analysis (and many other
analyzes). The selected two-factor solution stresses correlated factors of impaired
glucose metabolism and impaired lipid metabolism. This solution does not assign
hypertension a separate factor which is consistent with epidemiologic evidence that
insulin resistance and lipid metabolism play a role in the pathogenesis of hyperten-
sion rather than hypertension being a physiologic phenotype [22]. Moreover, there
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is no strong evidence of insulin resistance being dominant in both the glucose and
lipid domains.
Several limitations of this study should be considered. First, the data consider a
multiethnic cohort while MBS may express itself differently across ethnic groups and
gender. Note, however, that the specification of a factor model through inequality
constraints would also be helpful in assessing measurement (factorial) invariance
across groups. Second, MBS may develop with age and with the advent of DM and
CVD, implying that the data might represent a snap-shot of phenotypic expressions
related to MBS. Third, the proposed factor analytic strategy is more involved than
routine uses of EFA and regular CFA in the sense that it requires more computation
time and puts higher cognitive demands on the researcher. Nevertheless, these
drawbacks are felt to be outweighed by the advantages of the strategy and the
proposed steps are deemed to form a viable analytic alternative for other studies
seeking to use FA.
The findings suggest that there are two correlated pathophysiological domains
underlying the phenotypic expressions of MBS included in the analysis. These
domains are characterized by impaired glucose metabolism and impaired lipid me-
tabolism, respectively. These findings indirectly point to the possibility that several
different pathogenic processes need to coincide in order to be able to identify a MBS
construct. It might be timely to postulate the possible existence of a multifactorial
aetiology.
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Appendix: Basics of Factor Analysis
The unrestricted factor model is considered. Let ZT ≡ [z1, . . . , zn] define (stan-
dardized) p-variate observation vectors on i = 1, . . . , n subjects, such that zTi ≡
[zi1, . . . , zip] ∈ Rp denotes a realization of the random vector ZTi ≡ [Zi1, . . . , Zip] ∈
Rp. Also, let ΞT ≡ [ξ1, . . . , ξn] define m-variate vectors of latent factor scores on
n subjects with ξTi ≡ [ξi1, . . . , ξim] ∈ Rm.
The model (1) maintains the following assumptions: (i) zi ⊥⊥ zi′ ,∀i 6= i′; (ii)
rank(Λ) = m; (iii) i ∼ Np(0,Ψ), with Ψ ≡ diag(ψ11, . . . , ψpp), and ψjj > 0;
(iv) ξi ∼ Nm(0,Φ); and (v) ξi ⊥⊥ i′ ,∀i, i′. The likelihood for the observations
conditional on the realization of Ξ can then be expressed as:
L(µ,Λ,Ξ,Ψ,Φ; Z) =
n∏
i=1
f(zi|µ,Λ, ξi,Ψ,Φ)
=
n∏
i=1
(2pi)−
p
2 |Ψ|− 12 exp
{
−1
2
Ti Ψ
−1i
}
,(2)
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where i = zi −µ−Λξi. Marginalizing over ξi the likelihood of the observed data
can be obtained:
L(µ,Λ,Ψ,Φ; Z) =
n∏
i=1
∫
f(zi|µ,Λ, ξi,Ψ,Φ)g(ξi|Φ) ∂ξi
=
n∏
i=1
(2pi)−
p
2 |ΛΦΛT + Ψ|− 12(3)
× exp
{
−1
2
(zi − µ)T[ΛΦΛT + Ψ]−1(zi − µ)
}
,
giving that the factor decomposition constrains the covariance structure of the zi
to
(4) Σ = ΛΦΛT + Ψ.
Then, for existence (vi), generally (p − m)2 − p − m > 0, simply stating that
the number of nonredundant elements in the sample correlation matrix S must be
greater than or equal to the number of freely estimable parameters in Σ, which
places an upper bound on m.
Now, Φ ∈ Rm×m denotes the factor covariance matrix, giving that (4) represents
an oblique model in which the latents may share covariation. Note that, for positive
definite Φ, we may always find V ∈ Rm×m such that Φ = VVT, and
(5) Σ = ΛΦΛT + Ψ = (ΛV)[V−1Φ(V−1)T](ΛV)T + Ψ = (ΛV)(ΛV)T + Ψ.
Equation (5) implies that any oblique representation has equivalent orthogonal
representations. The orthogonal representation makes the following statements on
identification less involved.
It is well known that for given Λ and Ψ, the former is defined uniquely only up to
rotation. Correspondingly the FA literature has focussed mainly on identification
of Ψ. The main result of which is that if assumption (vi) holds, Ψ is almost
surely identified [77]. This result is however contingent upon the rank of Λ. The
implications of a failure to abide model assumption (ii) were explored by Anderson
and Rubin [78] and Geweke and Singleton [79]. Suppose that rank(Λ) = r < m.
Then there exists a matrix Q ∈ Rm×(m−r) for which (ΛV)Q = 0 and QTQ = Im−r,
such that for any M ∈ Rp×(m−r) with mutually orthogonal rows
(6) Σ = (ΛV)(ΛV)T + Ψ = (ΛV + MQT)(ΛV + MQT)T + (Ψ−MMT).
Equation (6) implies that no consistent estimator of Ψ exists if Λ fails to be of full
column rank. This may induce corresponding multimodalities in the densities of Ψ
and Λ [74], and is related to the choice of factor dimensionality and the possibility
of retaining too many factors.
The FA model also copes with an inherent indeterminacy of the parameters,
being: Rotational indeterminacy of the factor solution. Assume that R ∈ Rm×m is
an arbitrary nonsingular matrix. Returning to the implied covariance structure of
the observed data, we then have
(7) Σ = ΛΦΛT + Ψ = (ΛR)[R−1Φ(RT)−1](ΛR)T + Ψ,
implying that there is an infinite number of alternative matrices Λ‡ = ΛR and
Φ‡ = R−1Φ(RT)−1 that generate the same covariance structure Σ. The operation
Λ 7→ ΛR is termed ‘rotation’. Thus, in any solution, Λ can be made to satisfy m2
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additional conditions, which is naturally equivalent to the number of independent
elements of R.
From the above it is clear that any method of estimation requires at a minimum
m2 restrictions on Λ and Φ. The EFA tradition usually achieves this by requiring
that Φ = Im and Λ
TΨ−1Λ be diagonal accompanied by an order condition on the
diagonal elements. These restrictions are arbitrary such that whence estimation
is settled EFA traditionally endeavors on applying a rotation that satisfies certain
criteria for interpretation purposes. Peeters [68] has given minimal conditions for
the formulation of a rotationally unique confirmatory unrestricted factor model that
cancels the need for post-hoc rotation.
Appendix: A Primer on Bayesian Statistics
The Bayesian viewpoint is distinct from the classical approach to statistics. Let
Θ denote a model-specific collection of unknown parameters of continuous metric.
The frequentist approach solely utilizes the likelihood of the observed data L(Θ; X),
in that a retrospective evaluation is made of a certain statistic used to estimate Θ
over all possible X values conditional on the true unknown Θ which is deemed
fixed. The Bayesian approach views Θ as random. This allows for probability
statements about pi(Θ|X), the distribution of model parameters conditioned on
the observed data. To provide the mentioned conditional probabilities, a joint
probability function for Θ and X must be provided for. To this purpose a prior
distribution pi(Θ) must be specified, which reflects the formalized knowledge or
uncertainty about the parameters before observation of the data. Using a basic
property of conditional probability known as Bayes’ rule [80, 81], one obtains the
posterior distribution as:
(8) pi(Θ|X) = L(Θ; X)pi(Θ)∫
L(Θ; X)pi(Θ) ∂Θ
.
Expression (8) encapsulates the core machinery of Bayesian statistics, whose flex-
ibility has proven to extend to complex problems (consult, for example [82, 83]).
The denominator in (8) is called the prior predictive density or marginal likelihood
and is key in Bayesian model selection.
Let us shortly review Bayesian model selection for latent variable models. Let ϑ
denote latent data. For the factor model described in Section ‘The Factor Analytic
Model’, Θ = {µ,Λ,Ψ,Φ} and ϑ = Ξ. Now, let g(ϑ|Θ) denote the density of
latent data ϑ given Θ and assume that the complete data likelihood consists of
L(Θ,ϑ; X)g(ϑ|Θ). Suppose also that the prior pi(Θ) is available for the unknown
model parameters Θ. The marginal likelihood is then expressed as:
(9) m(X) =
∫
L(Θ,ϑ; X)pi(Θ)g(ϑ|Θ) ∂(Θ,ϑ).
The marginal likelihood expresses the likelihood of the data conditional on the
model entertained. This quantity is of import in the construction of the Bayes
factor, the main Bayesian model selection criterion. Suppose that S competing
models Ms are under consideration, for s = 1, . . . , S. The Bayes factor of Ms to
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Ms′ is then expressed as [84,85]:
(10) Bss′ =
ms(X)
ms′(X)
=
∫
Ls(Θs,ϑs; X)pis(Θs)gs(ϑs|Θs) ∂(Θs,ϑs)∫
Ls′(Θs′ ,ϑs′ ; X)pis′(Θs′)gs′(ϑs′ |Θs′) ∂(Θs′ ,ϑs′)
.
The Bayes factor embodies the ratio of posterior odds to prior odds for the models
under consideration. The expression in (10) resembles a likelihood ratio. But in-
stead of evaluating the respective likelihoods at the maximum likelihood estimates,
the parameters are integrated out with respect to the priors. The BF thus can be
viewed as representing a ‘weighted’ likelihood ratio that provides a measure “of the
evidence provided by the data in favor of one scientific theory, represented by a
statistical model, as opposed to another” [66]. The Bayes factor behaves like a nat-
ural Occam’s razor, as model fit and complexity are accounted for in the marginal
likelihood [86,87]. For interpretation the quantity (10) can be referred to half-units
on the log10 scale (Appendix B of [85]) or one can consider 2 logeBss′ [66], which is
on the same scale as likelihood ratio statistics. Another interpretational aid might
be the posterior model probability, defined as [72]:
(11) P (Ms′ |X) =
(
S∑
s=1
ps
ps′
·Bss′
)−1
.
In (11) ps denotes the prior probability one assigns to model Ms being best,∑S
s=1 ps = 1. The posterior model probability P (Ms′ |X) gives the posterior proba-
bility, given the batch of models under consideration, that model Ms′ is the correct
model for the data at hand. A normalization of the Bayes factor ensues when letting
ps = S
−1 ∀s.
The Bayes factor as a model selection criterion has several advantages (cf., [66,
73]): (i) It provides both a measure of evidence against a competing model and
a measure of support for the alternative model; (ii) It will not by default favor
the alternative model in (very) large samples; (iii) It allows one to take model
uncertainty into account, thus providing a consistent quantity for the comparison of
a multitude of competing models; (iv) It can handle the comparison of both nested
and nonnested models. For an introduction to Bayesian statistics see [82, 83]. For
Bayesian factor analysis see [73,88]. For inequality-constrained-model selection for
Bayesian FA as well as Bayesian treatments of both EFA and CFA, see [67].
Appendix: Results Factor Analytic Approach Weiss et al. [69]
Table 2 contains the results of the little jiffy approach to the data as given in
the original study (Table 3 in [69]). A three-component solution was obtained in
which the first component was interpreted as ‘obesity and glucose metabolism’, the
second as ‘dyslipidemia’, and the third as ‘blood pressure’.
Appendix: Reproduced Correlation Structure
Table 3 contains the sample correlations, the correlations reproduced by the
factor analysis, and the residual correlations (sample correlation minus reproduced
correlation).
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Table 2. Results little jiffy analysis on the data [69]
Components
1 2 3 Item
.44 .13 .06 BMI
.09 .83 .04 loge{trig.}
-.13 -.82 .06 HDL chol.
.76 .27 .15 loge{IR}
.72 -.14 .07 loge{GB}
.67 .10 -.06 loge{G2}
.15 .09 .79 SBP
.01 .09 .83 DBP
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SUPPLEMENTARY MATERIAL
Tables S1 and S2 below list overviews of published studies on the MBS em-
ploying factor analytic techniques. Table S1 lists studies among the child and
adolescent cohort. Table S2 lists studies among subjects other than children and
adolescents. Studies were found using the PubMed search engine [89] by pairing the
search term “factor analysis” with each in {“metabolic syndrome”, “insulin resis-
tance syndrome”, and “syndrome X”} (the names that are regularly used to refer
to the MBS). By usage of these terms English-language publications were sought
with (online) publication dates from 1994 (year of publication of the seminal article
by [26]) to January 2014. See [90, 91] and the online supplement to [53] for addi-
tional (complementary) overview tables. Please consider the remarks below for full
understanding of Tables S1 and S2.
Eligibility criteria. Included studies focus their factor analytic efforts, as in
the main text, on variables of a metabolic nature. Studies that focus mainly on
hemostatic, inflammatory, lifestyle, or diet variables were excluded. Studies that
provided no information on their factor analytic procedure (extraction, retention,
and rotation) were also excluded. In addition, studies that considered binary or
categorical variables in standard factor models were also not considered.
Data extraction. If a study that focuses on the mentioned variables for exclusion
in addition ran a factor analytic procedure on the traditional metabolic variables,
then only the results of the analysis on the metabolic variables are reported. When
study and validation cohorts were available in a certain study, only the study co-
hort is reported when results comply. Also, when FA was performed on various
(sub)sets of variables, we chose to report the FA on the combination of items most
in concurrence with the data (re-)analyzed in this study.
When representing EFA efforts (including PCA) the description of the factors is
based on the loading cut-offs chosen by the authors of the original studies. When
representing CFA efforts in the tables below, we focus on the factor structure, not
on other model details such as correlated error variables. When a higher-order
factor model is utilized in a certain study only the first-order factors are described
(the second-order factor is always termed ‘MBS’). It is however explicitly indicated
when a higher-order model is fitted. In addition, we only report final models when
describing CFA efforts. Details such as usage of modification indices can be found
in the studies themselves.
The assessment of the stability of the factor analytic model is generally known as
the issue of ‘measurement invariance’. This issue arises in longitudinal data (is the
model stable over the measured time-points) or when the total sample is considered
to consist of subgroups (is the model stable over all subgroups that make up the total
sample). Invariance can be studied on the level of the model structure (number
of factors and factor structure) or, given a certain model structure, on the level
of the parameter values. A formal approach would be to perform multiple group
analyses, possibly paired with a hierarchy of invariance tests (see e.g., [92]). This
formal approach is strongly tied to CFA. An informal approach, usually performed
in EFA-type analyses, would be to perform separate EFA’s (or PCA’s) on the data
from the respective subgroups or time-points and to assess loosely if the model is
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stable. In the tables below we use ‘assessment of measurement invariance’ to refer
to the more formal approach while we use ‘subgroup analyzes’ to refer to the more
informal approach. In the tables below it is explicitly indicated if, within a certain
study, factor analytic results differ over the various subgroups or time-points. If the
model structure is considered invariant (in the original study) this will be designated
with ‘structure considered invariant’. If model structure and parameter values are
considered invariant (in the original study) this will be designated with ‘model
considered invariant’.
Reading the tables. In the tables below ‘approach’ refers to the factor analytic
approach taken and ‘factors’ refers to either common factors (in the case of a true
factor analytic approach) or principal components (in case of a PCA approach).
The sample size given is the size of the sample included in the factor analytic
efforts. Characteristics refer to the characteristics of the sample included in the
FA.
Note that in the description of factors the ordering is of import in the PCA
approach and in an EFA approach with certain rotation criteria. The factors then
can be understood as being in descending order of (percent of) variance explained
(in the observed variables). In a CFA approach, the stated ordering of factors is
arbitrary. The numbering in this latter case is solely to convey the number of
factors modelled.
The reported studies are ordered according to year of publication. While the
metabolic variables may at first seem to differ widely between the included studies,
one may note that in many cases surrogate measures are used. For example, often
the apolipoproteins B and A-I are used as surrogates for the LDL and HDL choles-
terol fractions, respectively. Note also that the measures for insulin resistance can
vary over studies, e.g., fasting and postload insulin, HOMA-IR, or the intravenous
glucose tolerance test are some of the measures that are oft-used. In addition, the
tables use ‘/’ to designate a ratio, e.g., trig./HDL chol. indicates the triglycerides
over HDL cholesterol ratio.
The tables utilize, next to the abbreviations used in the main text, the following
additional abbreviations:
: %BF = percent body fat; 17HP = 17-hydroxyprogesterone; Adi =
adiponectin; Apo A-I = apolipoprotein A-I; Apo B = apolipoprotein B;
AST = abdominal skinfold thickness; BW = body weight; CASPIAN =
Childhood and Adolescence Surveillance and Prevention of Adult Non-
Communicable Disease; FFFA = fasting free fatty acids; FG = fasting
glucose; FI = fasting insulin; fib. = fibrinogen; FT = free testosterone;
HbA1c = glycated hemoglobin; HC = hip circumference; HDL2 = high
density lipoprotein 2 cholesterol; HDL tot. = total high density lipoprotein
cholesterol; IAF = (CT-measured) intra-abdominal fat area; IAI = Insti-
tuto Auxologico Italiano; IMGD = insulin-mediated glucose disposal; IS =
insulin sensitivity; IVGTT = intravenous glucose tolerance test; LDL chol.
= high density lipoprotein cholesterol; LDL-PPD = low-density lipoprotein
peak particle diameter; LR = likelihood ratio; MAP = mean arterial pres-
sure; ML = maximum likelihood; NFG = non fasting glucose; NHLBI =
National Heart, Lung, and Blood Institute; NOx = nitric oxide metabolites;
PAI-1 = plasminogen activator inhibitor-1; PAL = physical activity level
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(minutes/week); PCDD/Fs = polychlorinated dibenzo-p-dioxin, dibenzo-
furans persistant organic pollutants; PFFA = postload free fatty acids; PG
= postload glucose; PI = postload insulin; PIn = ponderal index; RA =
renin activity; SSK = subscapular skinfold; SSPG = steady state plasma
glucose; S:T = subscapular to triceps; SuRFNCD = Surveys of Risk Fac-
tors of Non-Communicable Diseases; TC = total cholesterol; TER = trunk
extremity ratio; TFM = trunk fat mass; tria. = triacylglycerols; TSI =
Torres Strait Islander; TTTS = trunk-to-total skinfolds; UA = uric acid;
U:C = urinary albumin - creatinine ratio; WBC = white blood cell count;
WC = waist circumference; WHR = waist-to-hip ratio.
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Table S1: Factor analyzes of the MBS in the child and adolescent cohort
Study Characterization Approach Description factors
Chen et al. [93] - Bogalusa Heart Study Little jiffy 1. trig., HDL chol., FG, FI, PIn
- Biracial (black/white) community-based population 2. SBP, DBP, FI
- n = 4, 522 children, adolescents, and young adults
Chen et al. [94] - Bogalusa Heart Study Little jiffy, ethnic Whites
- Biracial (black/white) community-based population subgroup analyzes 1. %BF, SBP, DBP
- n = 264 (132 whites, 132 African Americans) 2. %BF, HDL chol., trig.
3. %BF, IR, RA
African Americans
1. %BF, SBP, DBP
2. HDL chol., trig.
3. %BF, IR
Dwyer et al. [95] - Tasmanian Infant Health Study EFA, factor retention based 1. SBP,DBP
- Children from 1989 singleton births, Tasmania on LR testing, extraction by 2. FI, FG
- n = 298 8-year-olds principal axis factoring, 3. trig., HDL chol., LDL chol.
Harris-Kaiser rotation (oblique)
Moreno et al. [96] - Schoolchildren, Zaragoza, Spain Little jiffy, obesity Non-obese
- n = 142 (74 non-obese, 68 obese) subgroup analyzes 1. WC, BMI, FI, trig., TTTS, HDL chol., Leptin, UA
2. DBP, SBP
3. trig., HDL chol., Leptin, UA
4. FI, FG
Obese
1. BMI, WC, Leptin, DBP, SBP
2. DBP, TTTS, UA, SBP
3. FI, FG, trig.
4. HDL chol., trig.
Lambert et al. [36] - Quebec Child and Adolescent Health and Social Survey Little jiffy, with 9-y-olds
- Quebecian youth aged 9, 13, and 16 relaxed Guttman-Kaiser 1. BMI, FI, FG
- n = 2, 223 (700 9-y-olds, 716 13-y-olds, 817 16-y-olds) rule, age subgroup 2. BMI, FG, trig., HDL chol.
analyzes 3. SBP, DBP
13-y and 16-y-olds
1. BMI, FI, trig., HDL chol.
2. SBP, DBP
3. FI, FG
Park et al. [97] - School-going volunteers, urban South Korea PCA, Guttman-Kaiser rule, Boys
- Middle and high-school students aged 13-18 uspecified orthogonal 1. BMI, %BF, WC, LDL chol., trig., Leptin
- n = 148 (68 boys, 80 girls) rotation, gender subgroup 2. SBP, DBP
analyzes 3. FG, LDL chol., HDl chol.
Girls
1. BMI, %BF, WC, Leptin, FG
2. SBP, DBP
3. LDL chol., HDL chol., trig.
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Table S1 (Continued)
Study Characterization Approach Description factors
Weiss et al. [69] - Multiethnic, multiracial cohort Little jiffy 1. BMI, HOMA-IR, FG, PG
- Nondiabetic overweight children and adolescents 2. trig., HDL chol.
- n = 464 3. SBP, DBP
Goodman et al. [98] - Princeton School District Study Little jiffy 1. FG, WC, BMI, fib.
- School-based study, Cincinnati, Ohio, USA 2. LDL chol. TC
- Nondiabetic 7th to 12th graders 3. FG, FI, trig., HDL chol.
- n = 212 (subsample with BP measurements) 4. SBP, DBP
Retnakaran et al. [99] - Sandy Lake Health and Diabetes Project EFA, factor retention based 1. WC, %BF, BMI, trig., FI
- Nondiabetic children aged 10-19 on scree plot, extraction by 2. trig., HDL chol., FG, PG, FI
- n = 231 principal axis factoring, 3. SBP, DBP
oblique rotation (Promax)
Ghosh [100] - Calcutta, India Little jiffy, gender Boys
- Apparently healthy Asian Indian adolescents subgroup analyzes 1. WC
- n = 400 (200 boys, 200 girls) 2. S:T
3. TC, trig., FG
4. SBP, DBP, MAP
Girls
1. WC, S:T
2. WC, S:T
3. TC, trig., FG
4. SBP, DBP, MAP
Goodman et al. [101] - Princeton School District Study Little jiffy, baseline Baseline
- School-based study, Cincinnati, Ohio, USA and 3-year follow-up 1. FI, BMI, WC
- n = 1, 098 subgroup analyzes 2. FI, HDL chol., trig., FG
3. DBP, SBP
Follow-up
1. FI, BMI, WC, FG
2. HDL chol., trig.
3. DBP, SBP
Kelishadi et al. [102] - CASPIAN Study Little jiffy, subgroup Non-MBS
- Subjects from 6 provinces in Iran, aged 6 to 18 analyzes by age and 1. TC, LDL chol.
- n = 4, 811 (678 ATPIII MBS, 4,133 non-MBS) MBS-designation 2. trig., HDL chol., FG
3. WC, BMI
4. DBP, SBP
MBS
1. TC, LDL chol., trig.
2. HDL chol., FG, WC, BMI
3. WC, DBP, SBP
Li et al. [103] - National Health and Nutrition Examination Survey CFA, ML estimation, 1. WC, trig., FI, SBP
- Adolescents aged 12-17 assessment measurement (Model considered invariant)
- n = 1, 262 invariance across sex and
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Table S1 (Continued)
Study Characterization Approach Description factors
ethnicity
Ng et al. [104] - Hong-Kong Chinese adolescents Little jiffy, gender Boys
- Aged 12-19 subgroup analyzes 1. BW, WC, BMI
- n = 2, 102 (958 boys, 1,144 girls) 2. SBP, DBP
3. trig., HDL chol., LDL chol.
4. FG
Girls
1. BW, WC, BMI
2. SBP, DBP, FG
3. trig., HDL chol.
4. LDL chol.
Ramachandran et al. [105] - School-based survey, Chennai, India PCA, component retention Boys
- Children aged 12-19 and rotation (orthogonal) 1. WC, SBP, DBP
- n = 2, 640 (1,323 boys, 1,317 girls) unspecified, gender 2. trig. WC, FG, FI
subgroup analyzes 3. HDL chol., trig., FG
Girls
1. WC, SBP, DBP, FI
2. HDL chol., trig., WC, FI
3. FG, FI
Goodman et al. [56] - Fels Longitudinal Study CFA, assessment invariance None of the models
- Focus on developmental puberty stages of 3 alternative models gave (consistent)
- n = 442 (1-factor model, 4-factor model, adequate fit (across
2nd-order factor model) across
developmental puberty stages
Mayer-Davis et al. [106] - SEARCH for Diabetes in Youth Study CFA, ML estimation, 1. BMI, WC
- Type 1 and Type 2 diabetics, aged 10-22 assessment various CFA models 2. trig., HDL chol.
- n = 1, 293 (1,198 Type 1, 95 Type 2) (1-3 factors), assessment 3. DBP, SBP
measurement invariance (Model considered invariant)
across diabetes type
Noto et al. [107] - Primary and secondary schools, Serre Calabre Montane, Italy Little jiffy, gender 1. WC, BMI, age, SBP
- Schoolchildren aged 7-14 subgroup analyzes 2. HDL chol. trig.
- n = 1, 629 (859 boys, 770 girls) 3. SBP, DBP
4. FG
(Structure considered invariant)
Ghasemi et al. [108] - Tehran Lipid and Glucose Study Little jiffy, subgroup Total sample
- District 13 of Tehran, Iran analyzes w.r.t. 1. SBP, DBP, WC, BMI
- n = 851 (88 with MBS, 236 overweight) MBS-designation and weight 2. trig., HDL chol., WC, BMI
3. FG, NOx
MBS
1. WC, BMI
2. trig., HDL chol.
3. SBP, DBP
4. FG, NOx
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Table S1 (Continued)
Study Characterization Approach Description factors
Overweights
1. SBP, DBP, WC
2. trig., HDL chol., WC
3. FG, BMI, NOx
Mart´ınez-Vizca´ıno et al. [109] - Children from 20 schools in Cuenca, Spain CFA, usage of parceling, 1. WC, trig./HDL chol., FI, MAP
- Children aged 10-13 assessment measurement (Model considered invariant)
- n = 1, 020 invariance across gender
and physical activity
Khader et al. [43] - Household sample from 12 governorates, Jordan Little jiffy, subgroup 1. BMI, WC
- Children and adolescents analyzes w.r.t. gender 2. DBP, SBP
- n = 655 and age 3. HDL chol., trig.
4. FG
(Structure considered invariant)
Mart´ınez-Vizca´ıno et al. [110] - European Youth Heart Study CFA, ML estimation, 1. WC, trig./HDl chol., FI, MAP
- 6-year follow-up study usage of parceling, (Model considered invariant)
- Swedish and Estonian children aged 9 at start assessment measurement
- n = 634 (174 Swedish, 460 Estonian) invariance across ethnicity
and time
Olza et al. [111] - Children from 3 regions of Spain Little jiffy 1. SBP, FG, HOMA-IR
- Obese Caucasian children aged 5-14 2. HDL chol., trig.
- n = 478 3. BMI, SBP
Gurka et al. [112] - National Health and Nutrition Examination Survey CFA, ML estimation, 1. BMI, SBP, HDL chol., trig., FG
- Non-Hispanic blacks, whites, and Hispanics aged 12-19 assessment measurement (Structure considered invariant)
- n = 4, 147 invariance across
sex-ethnicity combinations
Hong et al. [113] - Ho Chi Minh City, Vietnam Little jiffy, gender Boys
- Urban high-school students subgroup analyzes 1. BMI, WC
- n = 617 (284 boys, 333 girls) 2. SBP, DBP, LDL chol.
3. trig., HDL chol.
Girls
1. BMI, WC
2. SBP, DBP, LDL chol.
3. trig., HDL chol.
4. LDL chol., FG
Suchday et al. [114] - Students liberal arts college, Mumbai, India Little jiffy 1. SBP, WHR, DBP, BMI, FI
- Students aged 15-23 2. TC, trig.
- n = 112 3. FG, BMI, FI
Wang et al. [115] - Beijing Child and Adolescent Metabolic Syndrome Study Little jiffy, gender Non-parceling, boys
- Schoolchildren aged 6 to 18 subgroup analysis, 1. WC, trig., HDL chol., HOMA-IR, FI, Leptin, Adi
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Table S1 (Continued)
Study Characterization Approach Description factors
- n = 3, 373 (1,717 boys, 1,656 girls) followed by parceling 2. WC, SBP, DBP
3. FG, HOMA-IR, FI
Non-parceling, girls
1. WC, FG, HOMA-IR, FI, Leptin
2. WC, trig., HDL chol., Leptin, Adi
3. WC, SBP, DBP
Usage of parceling
1. WC, MAP, trig./HDL chol., Leptin/Adi
Table S2: Factor analyzes of the MBS in additional cohorts
Study Characterization Approach Description factors
Edwards et al. [26,116] - Kaiser-Permanente Women Twins Study Little jiffy 1. BW, WC, FI, FG
- Unrelated, nondiabetic women 2. FI, PI, FG, PG, SBP
- n = 281 3. trig., HDL chol., LDL-PPD
Donahue et al. [117] - Miami Community Health Study Little jiffy 1. UA, SBP, DBP, HDL chol., trig., WC, IMGD
- Nondiabetic African-Americans and non-Hispanic whites 2. FI, FG, DBP, IMGD
- n = 50
Meigs et al. [118] - Framingham Offspring Study Little jiffy, gender 1. FI, PI, BMI, WHR, HDL chol., trig.
- Nondiabetic men and women subgroup analyzes 2. GB, G2, FI, PI
- n = 2, 458 (1,150 men and 1,308 women) 3. BMI, SBP, DBP
(Structure considered invariant)
Edwards et al. [119] - Honolulu Heart Program Little jiffy, subgroup Nondiabetic
- (Non)diabetic elderly Japanese-American men analyzes according to 1. BW, WC, FI
- n = 3, 159 (2,760 nondiabetic and 399 diabetic) diabetic status 2. SBP, DBP
3. trig., HDL chol.
4. FG, FI
Diabetic
1. BW, WC
2. SBP, DBP
3. trig., HDL chol., FG
4. FG, FI
Gray et al. [120] - Strong Heart Study Little jiffy, subgroup Nondiabetic males
- American Indians analyzes by gender and 1. BMI, FI, FG
- n = 4, 228 (975 and 1,202 nondiabetic men and women, diabetic status 2. SBP, DBP
783 and 1,268 diabetic men and women) 3. HDL chol., trig., FI
Nondiabetic females
1. BMI, FI, FG
2. SBP, DBP
3. HDL chol., trig.
Diabetic males
1. SBP, DBP
2. HDL chol., trig., FG
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Table S2 (Continued)
Study Characterization Approach Description factors
3. HDL chol., BMI, FI
Diabetic females
1. SBP, DBP
2. HDL chol., trig., FG
3. BMI, FI
Leyva et al. [121] - RISC-2 Study Little jiffy 1. IR, FG, FI, Leptin
- Nondiabetic men 2. Leptin, IVGTT, S:T, UA, SBP, BMI
- n = 74 3. HDL chol., trig.
Chen et al. [122] - Nondiabetic residents Kinmen Taiwan Little jiffy, gender Males
- n = 8, 437 (3,659 men and 4,778 women) subgroup analyzes 1. SBP, DBP
2. FI, BMI, WHR, HDL chol., trig.
3. FG
Females
1. SBP, DBP
2. FI, BMI, WHR, HDL chol., trig.
3. FG, trig.
Sakkinen et al. [123] - Cardiovascular Health Study Little jiffy 1. BW, WC, FI, FG
- Elderly nondiabetics 2. PI, PG
- n = 322 3. SBP, DBP
4. trig., HDL chol.
Snehalatha et al. [124] - Urban cluster survey, Madras, India PCA, component retention Males
- Nondiabetic adults based on scree plot, 1. BMI, FG, PI, HOMA-IR
- n = 654 (396 men and 258 women) Varimax rotation, 2. BMI, SBP, DBP
gender subgroup analyzes 3. BMI, WHR, chol., trig.
Females
1. BMI, FG, PI, HOMA-IR
2. BMI, SBP, DBP
3. chol., trig.
4. BMI, WHR, HOMA-IR
Anderson et al. [125] - Chinese men and women EFA, factor retention 1. FI, FG, BMI, WC, IS
- n = 145 based on Guttman-Kaiser 2. BMI, MAP, WC
rule, Varimax rotation 3. HDL chol., WC, trig.
Hodge et al. [126] - Island of Mauritius Little jiffy, gender Males
- Nondiabetic adults subgroup analyzes 1. WHR, BMI, Leptin, trig., HDL chol., FA, PI
- n = 3, 068 (1,414 men and 1,654 women) 2. UA, SBP, DBP
3. FI, PI, FG, PG
Females
1. WHR, BMI, Leptin, trig., HDL chol., FI, PI, UA
2. FG, SBP, DBP
3. FI, PI, FG, PG
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Table S2 (Continued)
Study Characterization Approach Description factors
Shmulewitz et al. [127] - Pacific island of Kosrae, Micronesia PCA, component retention 1. BW, WHR, Leptin, FI
- Nondiabetic adults and rotation (orthogonal) 2. TC, trig., Apo B
- n = 628 unspecified 3. FG, SBP, DBP
4. Leptin, trig., Apo A-I
Adami et al. [128] - Obese Italian adults Little jiffy 1. trig., HDL chol., SBP, DBP
- n = 163 2. FI, HOMA-IR
3. BMI, Leptin, FG
Arya et al. [129] - San Antonio Family Diabetes Study Little jiffy 1. BMI, Leptin, FI
- Nondiabetic Mexican-Americans 2. DBP, SBP
- n = 261 3. HDL chol., trig.
Hanley et al. [33] - Insulin Resistance Atherosclerosis Study Little jiffy 1. BMI, WC, FG, PG, HOMA-IR, trig., HDL chol.
- Nondiabetic adults 2. DBP, SBP
- n = 1, 087 (See [33] for subgroup analyzes)
Hanson et al. [34] - Gila River Indian Community, Arizona, USA Little jiffy, usage Nondiabetics
- Adult Pima Indians of parceling, subgroup 1. FI×FG, PI×PG, FI/FG, PI/PG
- n = 1, 448 (1,918 nondiabetics, 470 diabetics) analyzes by diabetic 2. BW, WC
status 3. DBP, SBP
4. HDL chol., trig.
Diabetics
1. FI×FG, PI×PG, FI/FG, PI/PG
2. BW, WC
3. DBP, SBP
4. HDL chol., trig., FI×FG
Kue Young et al. [130] - Sample survey 3 contiguous regions of Canada Little jiffy 1. BMI, HC, WC
- Adult Indians, Inuit, and non-Aboriginal Canadians 2. SBP, DBP, TC
- n = 3, 930 (873 Indians, 387 Inuit, 2,670 non-Aborigines) 3. trig., HDL chol., FG
O’Dea et al. [131] - Aboriginal and Torres Strait Islander People, Australia Little jiffy, subgroup TSI, males
- Community-based risk factor survey analyzes by gender and 1. FG, PG, FI, trig., HDL chol., WHR
- n = 863 (643 Aborigines and 220 Islanders) ethnicity 2. FI, SBP, DBP, BMI, WHR
TSI, females
1. FG, PG, FI, trig., HDL chol., BMI, WHR
2. SBP, DBP
Aborigines, males
1. SBP, DBP, BMI, WHR
2. FG, PG, BMI, WHR
3. FI, trig., HDL chol., BMI
Aborigines, females
1. SBP, DBP
2. FG, PG
3. FI, trig., HDL chol., BMI, WHR
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Table S2 (Continued)
Study Characterization Approach Description factors
Choi et al. [132] - The South-West Seoul Study Little jiffy, gender Males
- Urban elderly nondiabetic Koreans subgroup analyzes 1. BMI, WHR, HDL chol., trig., PI, FI
- n = 1, 314 (249 men, 1,065 women) 2. SBP, DBP
3. PI, PG
4. FI, FG
Females
1. SBP, DBP
2. BMI, WHR, HDL chol., trig.
3. FG, PG, PI
4. BMI, WHR, FI, FG
Ford [35] - National Health and Nutrition Examination Survey Little jiffy, subgroup Males
- n = 6, 868 (3,410 men, 3,458 women) analyzes by gender, 1. HDL chol., trig., FI, WC, BMI, WHR, UA
ethnicity and age 2. SBP, DBP
3. FG, U:C
Females
1. FI, WC, BMI, WHR, UA
2. SBP, DBP
3. HDL chol., trig., FG
(See [35] for other subgroup analyzes)
Hanley et al. [133] - Sandy Lake Health and Diabetes Project EFA, retention based on (ao) 1. FI, WC, %BF
- Nondiabetic adult native Canadians scree plot, factor extraction 2. FI, WC, trig., HDL chol., Adi
- n = 728 (305 men, 423 women) by principal axis factoring, 3. FI, FG, PG
Varimax rotation
Howard et al. [134] - Women’s Health Initiative Little jiffy, ethnicity Whites
- Nondiabetic postmenopausal female adults subgroup analyzes 1. BMI, HC, WC, HOMA-IR, FI, FG
- n = 3, 083 (1,635 White, 802 Black, 390 Latino, 2. HOMA-IR, FI, HDL chol., trig., HDL2/HDL tot.
256 Asian/Pacific Islander 3. TC, LDL chol.
4. SBP, DBP
(Structure similar in other ethnic subgroups)
Novak et al. [135] - Go¨teborg, Sweden CFA, ML estimation 1. SBP, DBP
- Middle-aged Caucasian males 2. BMI, WHR
- n = 284 3. FI, FG
4. trig., HDL chol.
Shen et al. [52] - Normative Aging Study CFA, robust ML estimation, 1. FI, PI, FG, PG
- Male participants second-order factor taken 2. BMI, WHR
- n = 847 to reflect MBS, assessment 3. trig., HDL chol.
measurement invariance over 4. SBP, DBP
cardiovascular disease and (Structure deemed invariant)
age groupings
Tang et al. [136] - NHLBI Family Heart Study EFA, factor retention 1. BMI, WHR, SSK, trig., HDL chol., HOMA-IR,
- Probands’ family members based on on Guttman-Kaiser PAI-1, UA
- n = 2, 831 rule, factor extraction by 2. trig., LDL chol., TC
ML estimation, rotation 3. BMI, SSK
unspecified 4. trig., LDL chol.
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Table S2 (Continued)
Study Characterization Approach Description factors
Cai et al. [137] - San Antonio Family Heart Study Little jiffy 1. BW, BMI, WC, HC, %BF, FI, AST
- Nondiabetic Mexican-Americans 2. FG, PG, FI, PI
- n = 566 3. SBP, DBP
4. HDL chol., trig.
Jones et al. [138] - Spinal cord-injured men Little jiffy 1. %BF, PAL, TFM, PG, PI
- n = 20 2. PAL, TC/HDL chol., HDL chol., PI
3. FG, FI
Nelson et al. [139] - Swedish Adoption/Twin Study of Aging CFA, further approach 1. IS, MAP, WHR, TC/HDL chol.
- n = 1, 944 unspecified, usage of
parceling
Oh et al. [37] - Mokdong Study of Diabetes Prevalence PCA, component retention Males
- Urban Korean adults unspecified, Varimax rotation, 1. BMI, WC, FI
- n = 655 (206 men, 449 women) gender subgroup analyzes 2. FG, PG, FI
3. SBP, DBP
4. FI, trig., HDL chol.
Females
1. BMI, WC, SBP, DBP
2. FG, PG, FI
3. BMI, WC, FI, trig., HDL chol.
Wang et al. [140] - National Diabetes Survey China Little jiffy, gender Nondiabetic males
- Nondiabetic Chinese adults and diabetic status 1. BMI, WHR, FI, FG
- n = 934 (449 and 485 nondiabetic men and women, subgroup analyzes 2. SBP, DBP
132 and 173 diabetic men and women) 3. PI, FG, PG
4. TC, trig.
Nondiabetic females
1. BMI, WHR, FI
2. SBP, DBP
3. PI, FG, PG
4. TC, trig.
Diabetic males
1. SBP, DBP
2. UA, trig., FG, PG
3. BMI, WHR, FI
4. TC, FI, PI
Diabetic females
1. SBP, DBP
2. UA, FG, PG
3. BMI, WHR, trig., FI
4. TC, FI, PI
Ang et al. [38] - Singapore National Health Survey Little jiffy, subgroup Chinese males and females, Malay males
- Nondiabetic Chinese, Malay, and Asian Indian adults analyzes w.r.t. gender 1. HOMA-IR, BMI, WHR, HDL chol., trig.
- n = 4, 265 (1,671 Chinese, 281 Malay, 158 Indian and ethnicity 2. FG, PG, HOMA-IR
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Table S2 (Continued)
Study Characterization Approach Description factors
males; 1706 Chinese, 264 Malay, 146 Indian females) 3. BMI, WHR, SBP, DBP
Malay females
1. HOMA-IR, BMI, WHR, HDL chol., trig.
2. FG, PG, HOMA-IR
3. HOMA-IR, BMI, WHR, trig., SBP, DBP
Indian males
1. HOMA-IR, BMI, WHR, HDL chol., trig.
2. FG, PG, HOMA-IR
3. WHR, SBP, DBP
Indian females
1. HOMA-IR, BMI, WHR, HDL chol., trig.
2. FG, PG, HOMA-IR, WHR
3. BMI, WHR, SBP, DBP
Ghosh [39] - Employees Eastern Railway Government, India Little jiffy 1. WHR
- Middle-aged Bengalee Hindu men 2. TER
- n = 212 3. TC, trig., FG
4. SBP, DBP
Lin et al. [141] - Northern Manhattan Family Study Little jiffy 1. trig., HDL chol., FG, WC
- Subjects from Caribbean-Hispanic families 2. SBP, DBP
- n = 803
Mohan et al. [142] - Chennai Urban Rural Epidemiology Study Little jiffy, component 1. trig., HDL chol., HOMA-IR, Adi, WC
- Adult diabetic from Chennai, India retention not specified 2. WC, SBP, DBP
- n = 100
Liou et al. [143] - Taipei Veterans General Hospital Little jiffy 1. BMI, WC, FG, trig., HDL chol., UA
- Cross-sectional studies from Spain, Mauritius, and USA 2. SBP, DBP
- n = 393
Pladevall et al. [53] - CFA study using previously collected data CFA, ML estimation, 1. WC, HOMA-IR, trig./HDL chol., MAP
- Nondiabetic middle-aged Chinese men usage of parceling
- n = 4, 318
Shah et al. [54] - Insulin Resistance Atherosclerosis Study CFA, ML estimation 1. SBP, DBP
- Data as used in [33] 2. HDL chol., trig.
3. IS, PG, FG
4. WC, BMI
Shen et al. [144] - Miami Community Health Study CFA, ML estimation, 1. FI, FG
- Nondiabetic Caucasians, African and Cuban-Americans second-order factor 2. BMI, WC
- n = 517 taken to reflect MBS, 3. trig., HDL chol.
assessment measurement 4. SBP, DBP
invariance over gender, (Structure deemed invariant)
ethnicity and age groupings
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Table S2 (Continued)
Study Characterization Approach Description factors
Zanolin et al. [145] - Outpatients, Verona, Italy Little jiffy 1. FI, PI, BMI, HDL chol., trig., UA
- Caucasian nondiabetic hyperandrogenic women 2. BMI, DBP, SBP, FT
- n = 255 3. FG, PG, PI, trig., FT
4. PI, FT, 17HP
Chien et al. [146] - Chin-Shan Community Family Study Little jiffy 1. SBP, DBP, WC, BMI
- Adolescent probands and relatives, China 2. TC, LDL chol.
- n = 1, 227 3. HOMA-IR, FG, HDL chol., trig.
Razak et al. [147] - Study of Health Assessment and Risk in Ethnic Groups PCA, retention and 1. FG, PG, FI, PI, HOMA-IR, HbA1c, FFFA,
- Subjects from 4 ethnic groups from 4 regions, Canada rotation criteria PFFA
- n = 1, 078 unspecified 2. FI, PI, HOMA-IR, LDL chol., HDL chol.,
trig., PFFA
3. SBP, DBP
Ghosh [148] - Nondiabetic pre and postmenopausal Bengalee women Little jiffy, menopausal Premenopausal
- n = 200 (100 pre and 100 postmenopausal) subgroup analyzes 1. WC, WHR
2. TC, trig., HDL chol., LDL chol., FG
3. SBP, DBP
Postmenopausal
1. WC, WHR
2. WC, WHR, FG
3. TC, trig., HDL chol., LDL chol., FG
4. SBP, DBP
Lafortuna et al. [149] - Patients IAI, Piancavallo, Italy Little jiffy 1. FI, HOMA-IR
- Adult obese women 2. WHR, trig., HDL chol., FG
- n = 552 3. BW, WC
4. SBP, DBP
Reimann et al. [150] - Transition and Health during Urbanization Study Little jiffy, subgroup Rural
- Rural, semiurban, and urban Black South Africans analyzes w.r.t. 1. BMI, WC, FI, HDL chol.
- n = 448 (140 rural, 118 semiurban, 190 urban) urbanization 2. SBP, DBP, FI
3. trig., UA
4. FG, PG, HDL chol.
Semiurban
1. BMI, WC, trig.
2. SBP, DBP, HDl chol.
3. FG, FI
4. PG, HDL chol.
5. trig. UA
Urban
1. BMI, WC, HDl chol..
2. FG, FI, trig.
3. SBP, DBP
4. FG, PG, HDL chol.
Wu et al. [151] - Patients enrolled in a General Hospital, Taipei, Taiwan Little jiffy, glucose Normal glucose tolerance
- Participants in routine health check tolerance subgroup 1. SBP, DBP
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Table S2 (Continued)
Study Characterization Approach Description factors
- n = 509 (345 normal and 164 impaired glucose tolerance) analyzes 2. WHR, SSPG, trig., HDL chol.
Impaired glucose tolerance
1. SBP, DBP
2. WHR, SSPG, trig., HDL chol.
3. FG, trig.
Boronat et al. [57] - Telde Study CFA, ML estimation, 1. WC, trig./HDL chol., HOMA-IR, MAP
- Nondiabetic adult Canadians usage of parceling, (Structure deemed invariant)
- n = 902 assessment measurement
invariance across gender
Leone et al. [152] - Paris Investigations Pre´ventives et Cliniques Center PCA, retention based 1. HDL chol., trig.
- Subjects underwent health examination on scree plot, Varimax 2. SBP, FG
- n = 121, 965 rotation 3. WC
O¨hrvik et al. [153] - 75 year olds from Va¨ster˚as, Sweden EFA, factor extraction by 1. WC, HDL chol., trig., FG
- n = 401 (198 men, 203 women) principal axis factoring, 2. SBP, DBP
factor retention based on (Structure deemed invariant)
scree plot, Varimax rotation,
gender subgroup analyzes
Chang et al. [154] - Nondiabetic dioxin-exposed Taiwanese Little jiffy 1. HDL chol., trig., TC/HDL chol.
- n = 1, 409 2. SBP, DBP, serum PCDD/Fs
3. BW, WC
4. FG, HOMA-IR
Esteghamati et al. [155] - SuRFNCD 2007, Iran Little jiffy, gender Males
- Iranian adults subgroup analyzes 1. WC, HOMA-IR, SBP, Leptin
- n = 3, 001 (1,483 men, 1,518 women) 2. trig., HDL chol.
Females
1. WC, SBP, Leptin
2. trig., HDL chol.
Marsland et al. [156,157] - University of Pittsburgh Adult Health and behavior Project CFA, robust ML estimation, 1. SBP, DBP
- Non-hispanic White and African American subjects second-order factor taken 2. FI, FG
- n = 645 middle-aged community volunteers to reflect MBS 3. BMI, WC
4. HDL chol., trig.
Barbosa-Leiker et al. [158] - Spokane Heart Study CFA, robust ML estimation, 1. BMI, DBP, FG, HDL chol., trig.
- n = 604 assessment measurement (Model considered stable across time)
invariance over time points
Meshkani et al. [159] - Unrelated Iranian adults Little jiffy, gender Males
- Normal and impaired glucose tolerant subjects subgroup analyzes 1. BMI, WC, FI, UA
- n = 501 (266 men, 235 women) 2. SBP, DBP
3. FG, trig., HDL chol.
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Study Characterization Approach Description factors
Females
1. SBP, DBP
2. BMI, WC, FI
3. FG, trig., HDL chol., UA
Solera-Mart´ınez et al. [58] - First-year university students CFA, ML estimation, 1. HOMA-IR, trig./HDL chol., WC, MAP
- Universidad de Castilla-La Mancha, Spain usage of parceling, (Model considered invariant)
- n = 683 assessment measurement
invariance over gender
Azimi-Nezhad et al. [160] - Stanislas cohort (France) and Kharasan province (Iran) Extraction method unspecified, Iranian males and females, French males
- France: n = 1, 386 (678 men, 708 women) retention based on scree plot, 1. SBP, DBP, WC
- Iran: n = 1, 194 (589 men, 605 women) usage Varimax rotation, 2. trig., WC, FG, HDL chol.
subgroup analyzes w.r.t.
gender and ethnicity French females
1. SBP, DBP, WC, FG
2. trig., WC, HDL chol.
Esteghamati et al. [161] - Outpatient clinic, Vali-Asr hospital, Iran Little jiffy, subgroup Nondiabetics
- Iranian adults analyzes according to 1. WC, HOMA-IR, trig., SBP, Apo B
- n = 894 (327 nondiabetics, 567 diabetics) diabetic status 2. HDL chol., Apo A-I
Diabetics
1. WC, HOMA-IR, SBP
2. HDL chol., Apo A-I
3. trig., Apo B
Stevenson et al. [162] - Spokane Heart Study CFA, robust ML estimation 1. BMI, FG, HDL chol., trig., SBP
- Non-clinical healthy volunteers
- n = 434
Chirinos et al. [163] - Peruvian Study of Cardiovascular Disease Prevention CFA, ML estimation, 1. WC, SBP, DBP, trig., FG
- Andean Hispanic adults assessment measurement (Structure considered invariant)
- n = 2, 513 invariance over gender
Dusseault-Belanger et al. [164] - Centre Hospitalier Universitaire de Sherbrooke, Canada PCA, component retention 1. BW, MAP, FG, HDL chol., trig.
- Cohort with diverse medical histories based on parallel analysis [165], 2. MAP, FG
- n = 7, 213 rotation unspecified
Go´mez-Marcos et al. [166] - EVIDENT study CFA, ML estimation, Males
- Spanish adults usage of parceling, 1. BMI, trig./HDL chol., HOMA-IR, MAP
- n = 636 (258 men, 378 women) assessment measurement
invariance across gender Females
1. WC, trig./HDL chol., HOMA-IR, MAP
Gurka et al. [167] - National Health and Nutrition Examination Survey CFA, ML estimation, 1. WC, SBP, HDL chol., trig., FG
- Nondiabetic whites, blacks, and Hispanics assessment measurement (Structure considered invariant)
- n = 6, 870 invariance across gender
and ethnicity
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Study Characterization Approach Description factors
Huo et al. [168] - Residents Beijing, China CFA, ML estimation, Middle-aged men
- n = 7, 472 usage of parceling, 1. WC, trig./HDl chol., FG, MAP
assessment measurement
invariance across gender Women / Young and senior men
and age groups 1. WC, trig., FG, SBP
Nilsson et al. [169] - 75 year olds from Va¨ster˚as, Sweden PCA, retention based on, Males
- n = 396 (196 men, 200 women) Guttman-Kaiser rule, 1. FG, HDL chol., trig., WC
variability eigenvalues 2. DBP, SBP
assessed by bootstrapping, 3. FG, WBC
gender subgroup analyzes
Females
1. FG, HDL chol., trig., WC, WBC
2. DBP, SBP
Sabanayagam et al. [170] - Asian ethnic groups in Singapore Little jiffy Chinese
- Middle-aged to elderly subjects 1. NFG, HbA1c
- n = 9, 477 (3,167 Chinese, 3,082 Malays, 3,228 Indians) 2. trig., HDL chol., BMI
3. SBP, DBP
Malay
1. NFG, HbA1c
2. SBP, DBP
3. trig., HDL chol.
Indian
1. NFG, HbA1c
2. SBP, DBP
3. trig., HDL chol.
4. BMI
Smits et al. [171] - Subjects recruited by public advertisement CFA, ML estimation 1. trig., HDl chol., IS, SBP, DBP, IAF, PAI-1
- Nondiabetic individuals from Greater Seattle community
- n = 134
